150.85
price down icon5.20%   -8.27
pre-market  プレマーケット:  148.54   -2.31   -1.53%
loading
前日終値:
$159.12
開ける:
$157.54
24時間の取引高:
1.40M
Relative Volume:
1.38
時価総額:
$7.27B
収益:
$4.02B
当期純損益:
$-142.16M
株価収益率:
-51.03
EPS:
-2.9563
ネットキャッシュフロー:
$518.49M
1週間 パフォーマンス:
-15.07%
1か月 パフォーマンス:
-16.45%
6か月 パフォーマンス:
-10.11%
1年 パフォーマンス:
+8.61%
1日の値動き範囲:
Value
$149.98
$160.26
1週間の範囲:
Value
$149.98
$178.41
52週間の値動き範囲:
Value
$132.58
$228.88

Charles River Laboratories International Inc Stock (CRL) Company Profile

Name
名前
Charles River Laboratories International Inc
Name
セクター
Healthcare (1101)
Name
電話
781-222-6000
Name
住所
251 BALLARDVALE ST, WILMINGTON, MA
Name
職員
19,700
Name
Twitter
@criverlabs
Name
次回の収益日
2026-05-07
Name
最新のSEC提出書
Name
CRL's Discussions on Twitter

Compare CRL vs TMO, DHR, IDXX, WAT, A

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
CRL icon
CRL
Charles River Laboratories International Inc
150.85 7.66B 4.02B -142.16M 518.49M -2.9563
TMO icon
TMO
Thermo Fisher Scientific Inc
438.34 166.56B 45.20B 6.87B 6.75B 18.19
DHR icon
DHR
Danaher Corp
161.91 116.46B 24.78B 3.68B 5.29B 5.1743
IDXX icon
IDXX
Idexx Laboratories Inc
528.79 42.03B 4.45B 1.10B 1.06B 13.59
WAT icon
WAT
Waters Corp
329.22 32.72B 3.77B 449.25M 240.68M 7.8556
A icon
A
Agilent Technologies Inc
111.70 32.01B 7.07B 1.29B 993.00M 4.5355

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-14 開始されました RBC Capital Mkts Outperform
2025-12-15 アップグレード BofA Securities Neutral → Buy
2025-11-17 アップグレード Argus Hold → Buy
2025-11-06 アップグレード Robert W. Baird Neutral → Outperform
2025-10-06 アップグレード William Blair Mkt Perform → Outperform
2025-10-02 アップグレード Barclays Equal Weight → Overweight
2025-09-09 アップグレード Jefferies Hold → Buy
2025-07-09 アップグレード Citigroup Neutral → Buy
2025-05-23 アップグレード Redburn Atlantic Neutral → Buy
2025-05-14 アップグレード TD Cowen Hold → Buy
2025-05-08 アップグレード Evercore ISI In-line → Outperform
2025-03-21 ダウングレード Goldman Buy → Neutral
2025-03-04 アップグレード Citigroup Sell → Neutral
2025-03-03 アップグレード Redburn Atlantic Sell → Neutral
2025-01-22 ダウングレード William Blair Outperform → Mkt Perform
2025-01-17 ダウングレード UBS Buy → Neutral
2024-11-18 ダウングレード CLSA Hold → Underperform
2024-11-07 アップグレード CLSA Underperform → Hold
2024-10-23 開始されました CLSA Underperform
2024-10-14 開始されました Redburn Atlantic Sell
2024-10-07 ダウングレード Evercore ISI Outperform → In-line
2024-10-02 ダウングレード BofA Securities Buy → Neutral
2024-10-01 ダウングレード Citigroup Neutral → Sell
2024-08-08 ダウングレード JP Morgan Overweight → Neutral
2024-08-08 ダウングレード Robert W. Baird Outperform → Neutral
2024-06-28 ダウングレード Argus Buy → Hold
2024-06-07 開始されました Mizuho Neutral
2024-06-06 開始されました Goldman Buy
2024-02-15 ダウングレード Guggenheim Buy → Neutral
2023-09-13 開始されました TD Cowen Market Perform
2023-07-10 ダウングレード Citigroup Buy → Neutral
2023-02-23 アップグレード Guggenheim Neutral → Buy
2023-01-12 ダウングレード Jefferies Buy → Hold
2022-09-30 アップグレード Jefferies Hold → Buy
2022-08-25 開始されました Credit Suisse Outperform
2022-08-04 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-05-24 開始されました Guggenheim Neutral
2022-04-25 ダウングレード Jefferies Buy → Hold
2022-04-07 開始されました Stephens Overweight
2022-02-17 繰り返されました BofA Securities Buy
2022-02-17 アップグレード Citigroup Neutral → Buy
2022-02-17 繰り返されました Deutsche Bank Buy
2022-02-17 繰り返されました Morgan Stanley Overweight
2022-02-17 繰り返されました UBS Buy
2021-08-05 再開されました Credit Suisse Neutral
2020-12-16 ダウングレード Citigroup Buy → Neutral
2020-09-10 アップグレード Jefferies Hold → Buy
2020-07-01 アップグレード BofA Securities Neutral → Buy
2020-05-13 アップグレード UBS Neutral → Buy
2020-04-21 ダウングレード Jefferies Buy → Hold
2020-03-27 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-03-02 開始されました Deutsche Bank Buy
2020-02-18 アップグレード Wolfe Research Peer Perform → Outperform
2020-01-10 アップグレード Goldman Neutral → Buy
2020-01-08 開始されました Wells Fargo Overweight
2020-01-07 開始されました Citigroup Buy
2019-10-18 ダウングレード BofA/Merrill Buy → Neutral
2019-06-10 開始されました SVB Leerink Outperform
2019-04-30 再開されました Evercore ISI Outperform
2018-12-14 開始されました Deutsche Bank Buy
2018-10-09 開始されました UBS Neutral
2018-08-23 アップグレード Raymond James Mkt Perform → Outperform
2018-07-17 アップグレード RBC Capital Mkts Sector Perform → Outperform
2018-06-15 アップグレード KeyBanc Capital Mkts Sector Weight → Overweight
2018-02-14 アップグレード SunTrust Hold → Buy
すべてを表示

Charles River Laboratories International Inc (CRL) 最新ニュース

pulisher
May 17, 2026

Charles River Laboratories Tops Q3 Estimates, Tightens Full-Year Outlook - MSN

May 17, 2026
pulisher
May 17, 2026

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN

May 17, 2026
pulisher
May 15, 2026

Charles River Deepens Cell Therapy Role And Expands AI Pathology Platform - simplywall.st

May 15, 2026
pulisher
May 15, 2026

Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors - MSN

May 15, 2026
pulisher
May 15, 2026

Charles River (CRL) reliance on international sales: What investors need to know - MSN

May 15, 2026
pulisher
May 14, 2026

Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch

May 14, 2026
pulisher
May 14, 2026

Director Nancy Andrews gifts Charles River (CRL) shares to trust - Stock Titan

May 14, 2026
pulisher
May 14, 2026

Charles River Laboratories stock (US1591881009): Q1 earnings beat with updated FY guidance - AD HOC NEWS

May 14, 2026
pulisher
May 14, 2026

Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions - BioSpace

May 14, 2026
pulisher
May 13, 2026

Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

May 13, 2026
pulisher
May 13, 2026

Charles River Laboratories stock (US1591881009): Shareholders approve 2026 incentive plan - AD HOC NEWS

May 13, 2026
pulisher
May 13, 2026

Charles River (CRL) Partners with Medipost for Cell Therapy Adva - GuruFocus

May 13, 2026
pulisher
May 12, 2026

Charles River Laboratories (CRL) Announces Approval of 2026 Long-Term Incentive Plan - GuruFocus

May 12, 2026
pulisher
May 12, 2026

Director Steven Barg receives 1,438-share equity award at Charles River (NYSE: CRL) - Stock Titan

May 12, 2026
pulisher
May 12, 2026

Charles River Labs (CRL) director receives 1,438-share equity award grant - Stock Titan

May 12, 2026
pulisher
May 12, 2026

Director at Charles River (NYSE: CRL) receives 1,438-share stock grant - Stock Titan

May 12, 2026
pulisher
May 12, 2026

Charles River Laboratories stock (US1591881009): Q1 earnings beat but FY2026 forecast cut - AD HOC NEWS

May 12, 2026
pulisher
May 12, 2026

Number of shareholders of Charles River Laboratories International, Inc. – HAM:RV6 - TradingView

May 12, 2026
pulisher
May 12, 2026

Charles River Laboratories International Inc (CRL) Stock Down 5. - GuruFocus

May 12, 2026
pulisher
May 11, 2026

CRL Q1 Earnings & Revenues Top Estimates, Margins Crash, Stock Down - MSN

May 11, 2026
pulisher
May 11, 2026

Charles River Labs Shareholders Approve New Incentive Plan - TipRanks

May 11, 2026
pulisher
May 11, 2026

Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch

May 11, 2026
pulisher
May 11, 2026

Charles River (NYSE: CRL) investors approve 2026 incentive plan, pay and auditor - Stock Titan

May 11, 2026
pulisher
May 11, 2026

Charles River (NYSE: CRL) director Abraham Ceesay receives 1,438-share stock grant - Stock Titan

May 11, 2026
pulisher
May 11, 2026

Charles River Labs (NYSE: CRL) director Martin Mackay receives new stock grants - Stock Titan

May 11, 2026
pulisher
May 11, 2026

Director at Charles River (NYSE: CRL) gets 1,438-share equity grant - Stock Titan

May 11, 2026
pulisher
May 11, 2026

Charles River (NYSE: CRL) director receives stock grants instead of fees - Stock Titan

May 11, 2026
pulisher
May 11, 2026

Director at Charles River (NYSE: CRL) receives 1,438-share stock award - Stock Titan

May 11, 2026
pulisher
May 11, 2026

Director at Charles River (NYSE: CRL) receives 1,973-share equity award - Stock Titan

May 11, 2026
pulisher
May 11, 2026

Director Virginia M. Wilson (CRL) receives 1,438-share equity award at Charles River - Stock Titan

May 11, 2026
pulisher
May 11, 2026

Director James Foster gets 1,860 Charles River (NYSE: CRL) shares - Stock Titan

May 11, 2026
pulisher
May 11, 2026

symbol__ Stock Quote Price and Forecast - CNN

May 11, 2026
pulisher
May 11, 2026

Charles River (CRL) Enhances Digital Pathology Platform for Fast - GuruFocus

May 11, 2026
pulisher
May 11, 2026

Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow - 01net

May 11, 2026
pulisher
May 11, 2026

Charles River (CRL) Reliance on International Sales: What Investors Need to Know - Yahoo Finance

May 11, 2026
pulisher
May 11, 2026

Charles River expands AI-enabled digital pathology platform By Investing.com - Investing.com Canada

May 11, 2026
pulisher
May 11, 2026

Charles River Laboratories stock (US1591881009): Core business and market position - AD HOC NEWS

May 11, 2026
pulisher
May 10, 2026

Charles River Laboratories stock: Is CRL underperforming the healthcare sector? - MSN

May 10, 2026
pulisher
May 09, 2026

Is It Time To Rethink Charles River Laboratories (CRL) After Its Recent Price Rebound? - Yahoo Finance

May 09, 2026
pulisher
May 09, 2026

A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Momentum - simplywall.st

May 09, 2026
pulisher
May 09, 2026

Charles River Laboratories International Q1 Earnings Call Highlights - Barchart.com

May 09, 2026
pulisher
May 09, 2026

MSN Money - MSN

May 09, 2026
pulisher
May 09, 2026

Charles River Laboratories stock (US1591881009): Shares dip after recent run-up as analysts eye upsi - AD HOC NEWS

May 09, 2026
pulisher
May 08, 2026

Charles River Laboratories Q1 2026 earnings preview - MSN

May 08, 2026
pulisher
May 08, 2026

These Analysts Increase Their Forecasts On Charles River After Better-Than-Expected Q1 Results - Benzinga

May 08, 2026
pulisher
May 08, 2026

Charles River Laboratories International, Inc. Seeks M&A Opportunities - marketscreener.com

May 08, 2026
pulisher
May 08, 2026

Charles River Laboratories International, Inc. (NYSE:CRL) Q1 2026 Earnings Call Transcript - Insider Monkey

May 08, 2026
pulisher
May 08, 2026

Mizuho raises Charles River Labs stock price target on steady results - Investing.com Canada

May 08, 2026
pulisher
May 08, 2026

Charles River: Q1 Earnings Snapshot - theheraldreview.com

May 08, 2026
pulisher
May 08, 2026

Charles River Laboratories Q1 Adjusted Earnings Decline, Revenue Rises; Maintains 2026 Earnings Guidance - Moomoo

May 08, 2026
pulisher
May 07, 2026

Johnson Opportunity Fund's Charles River Laboratories International Inc(CRL) Holding History - GuruFocus

May 07, 2026

Charles River Laboratories International Inc (CRL) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
DGX DGX
$186.61
price down icon 0.71%
MTD MTD
$1,031.64
price down icon 0.99%
$142.54
price down icon 0.49%
$186.36
price down icon 5.36%
IQV IQV
$169.12
price down icon 0.91%
A A
$111.70
price down icon 1.38%
大文字化:     |  ボリューム (24 時間):